Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

MBD3L1 (Q8WWY6) - RNAi - Molecular Target Synopsis

Description Reference
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Barbie DA et al, (2009). Nature. 462 (7269) pp44-5
Selective Effect in K-Ras Mutant CelllinesBarbie DA et al, (2009). Nature. 462 (7269) pp44-5
Results of primary druggable genome v2 (DG2) Achilles heel siRNA screen in KMS11 multiple myeloma cellsRodger E Tiedemann et al, (2011). AACR.
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogeneLuo J et al, (2009). Cell. 137 (5) pp835-48
Large Scale Profiling of Kinase Dependencies in Cancer Cell LinesChris Lord et al, (2016)
Cell LineZ Score
z-scores below -2 indicate significant growth defects
Cell LineSum
Values shown are zero-centered cell viability B-scores
Negative scores indicate growth defects
Cell LineSum
Values shown are zero-centered cell viability B-scores
Negative scores indicate growth defects
Cell LineSum
All the values reported reflect the possibility of a shRNA to be synthetically lethal with mutant KRAS.
Criteria for synthetic lethality:
  • Mut log2 ratio ≤ -0.7
  • WT log2 ratio ≥ -2.0
  • Mut vs. WT log2 ratio difference of ≤ -0.7
  • p-value ≤ 0.3